KDNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KDNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Chinook Therapeutics's annualized Net Income for the quarter that ended in Jun. 2023 was $-267.78 Mil. Chinook Therapeutics's average Total Assets over the quarter that ended in Jun. 2023 was $516.34 Mil. Therefore, Chinook Therapeutics's annualized ROA % for the quarter that ended in Jun. 2023 was -51.86%.
The historical rank and industry rank for Chinook Therapeutics's ROA % or its related term are showing as below:
During the past 4 years, Chinook Therapeutics's highest ROA % was -20.74%. The lowest was -295.88%. And the median was -34.87%.
The historical data trend for Chinook Therapeutics's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chinook Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
ROA % | -295.88 | -36.71 | -20.74 | -33.02 |
Chinook Therapeutics Quarterly Data | ||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
ROA % | Get a 7-Day Free Trial | -26.59 | -37.58 | -42.98 | -43.06 | -51.86 |
For the Biotechnology subindustry, Chinook Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Chinook Therapeutics's ROA % distribution charts can be found below:
* The bar in red indicates where Chinook Therapeutics's ROA % falls into.
Chinook Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:
ROA % | = | Net Income (A: Dec. 2022 ) | / | ( (Total Assets (A: Dec. 2021 ) | + | Total Assets (A: Dec. 2022 )) | / count ) |
= | -187.865 | / | ( (563.803 | + | 574.084) | / 2 ) | |
= | -187.865 | / | 568.9435 | ||||
= | -33.02 % |
Chinook Therapeutics's annualized ROA % for the quarter that ended in Jun. 2023 is calculated as:
ROA % | = | Net Income (Q: Jun. 2023 ) | / | ( (Total Assets (Q: Mar. 2023 ) | + | Total Assets (Q: Jun. 2023 )) | / count ) |
= | -267.776 | / | ( (543.875 | + | 488.811) | / 2 ) | |
= | -267.776 | / | 516.343 | ||||
= | -51.86 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data. ROA % is displayed in the 30-year financial page.
Chinook Therapeutics (NAS:KDNY) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
ROA % | (Q: Jun. 2023 ) | ||
= | Net Income | / | Total Assets |
= | -267.776 | / | 516.343 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-267.776 / 4.032) | * | (4.032 / 516.343) |
= | Net Margin % | * | Asset Turnover |
= | -6641.27 % | * | 0.0078 |
= | -51.86 % |
Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Thank you for viewing the detailed overview of Chinook Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew James King | officer: Head of Renal Discovery | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
William Mariner Greenman | director | C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520 |
Eric Dobmeier | director, officer: President, CEO | C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Davis Jerel | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Mahesh Krishnan | director | 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Andrew Oxtoby | officer: Chief Commercial Officer | 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Tom Frohlich | officer: Chief Business Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Eric Bjerkholt | officer: Chief Financial Officer | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Dolca Thomas | director | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Srinivas Akkaraju | director | 565 EVERETT AVENUE, PALO ALTO CA 94301 |
Alan Glicklich | officer: Chief Medical Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Versant Voyageurs I, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Voyageurs I Parallel, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Venture Capital Vii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire • 07-17-2023
By PRNewswire • 07-12-2023
By ACCESSWIRE ACCESSWIRE • 06-20-2023
By Marketwired • 07-19-2023
By Marketwired • 07-16-2023
By PRNewswire PRNewswire • 06-12-2023
By PRNewswire • 07-03-2023
By Marketwired • 06-22-2023
By PRNewswire • 06-24-2023
By Marketwired • 07-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.